Full-Time

Senior Manager

Patient Affordability Analytics

Posted on 9/9/2026

Deadline 9/24/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$124.4k - $207.4k/yr

+ 17.5% bonus target + Share-based long-term incentive program

No H1B Sponsorship

New York, NY, USA + 1 more

More locations: United States

Hybrid

Hybrid schedule requires working onsite 2 to 3 days per week.

Bachelor's

Category
Data & Analytics (1)
Required Skills
Power BI
Python
SAS
Data Visualization
R
SQL
Tableau
Data Modeling
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Pfizer

See people who can refer or advise you

Requirements
  • A bachelor's degree is required.
  • At least 6 years of experience in copay, affordability, patient support services, or access and reimbursement analytics is required.
  • Demonstrated experience analyzing copay claims and longitudinal patient data, such as IQVIA, CoverMyMeds, Relay Health, or similar LAAD, copay, or eVoucher data sources.
  • Advanced proficiency in Excel and PowerPoint is required for building and interpreting program models and executive-ready presentations.
  • Working knowledge of visualization tools such as Power BI or Tableau.
  • Understanding of cost adjustment programs, including accumulators, maximizers, and alternative funding plans, and their impact on copay program design and Gross-to-Net performance.
  • Strong business acumen and the ability to move from a business question to a data-driven recommendation without heavy direction.
  • Written and verbal communication skills, including prior experience presenting findings and recommendations to functional leaders.
  • Comfort operating with ambiguity and driving new analytical approaches for previously unaddressed programs and questions.
  • Candidates must be authorized to be employed in the United States by any employer and have permanent work authorization in the United States.
Responsibilities
  • Support the delivery of data-driven insights for patient services programs and partner with functional leads to develop solutions that advance each brand's strategic priorities.
  • Serve as a key analytics partner to the Patient Affordability team, supporting leadership on program strategy and decision-making.
  • Support program optimization modeling by quantifying the impact of copay and affordability business rule changes, including benefit design, eligibility, and accumulator or maximizer mitigation, on program cost, patient access, and net sales.
  • Develop OpEx and Gross-to-Net forecasting models to support program budgeting and planning.
  • Translate primary and secondary claims data into clear, executive-ready insights that identify what is and is not working across programs.
  • Surface opportunities for program innovation and competitive differentiation, bringing findings forward with a recommended course of action.
  • Build and maintain program performance dashboards and metrics that provide partners with a consistent view of affordability program health.
  • Frame analyses and recommendations in terms of revenue impact and savings delivered for business reviews and investment conversations.
  • Partner with copay vendors and cross-functional teams to ensure data quality, program compliance, and conformity to rules and regulations.
  • Own ad hoc analytical requests from brand and access partners, exercising independent judgment on approach and prioritization.
Desired Qualifications
  • SQL, SAS, Python, R, or similar query experience is a plus.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approved Pfizer-BioNTech’s XFG COVID vaccine on August 27, 2026 for fall shipping.
  • Pfizer raised 2026 revenue guidance to $60.5 billion-$62.5 billion on August 4, 2026.
  • Padcev and Lorbrena grew in Q2 2026, proving post-Seagen oncology momentum.

What critics are saying

  • Eliquis loses U.S. exclusivity in 2028, opening a rapid generic cliff.
  • Arbutus filed international LNP patent suits on July 16, 2026 against Pfizer-BioNTech.
  • Comirnaty and Paxlovid remain shrinking as FDA narrows eligibility and COVID demand fades.

What makes Pfizer unique

  • Pfizer’s Seagen acquisition gives it a stronger oncology engine than pure-vaccine peers.
  • Eliquis and Vyndaqel diversify revenue beyond COVID, with Q2 2026 growth.
  • Pfizer’s global commercial scale still pushes products through pharmacies, hospitals, and governments.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

-5%

2 year growth

-5%
Yahoo Finance
Sep 8th, 2026
AbbVie beats Pfizer as top dividend stock with 53-year payout streak and 203% growth

AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.

Yahoo Finance
Aug 28th, 2026
Pfizer's updated COVID vaccine ships as FDA approves narrower rollout for over-65s and high-risk groups

Pfizer received FDA approval for its updated Comirnaty COVID-19 vaccine on Thursday, with deliveries to pharmacies and clinics beginning immediately. The company's shares were trading at $27.9079 on 28 August. However, the market opportunity has significantly narrowed from pandemic levels. Eligibility is now limited to adults aged 65 and older, plus higher-risk patients aged 5 through 64. Despite Comirnaty having distributed over five billion doses worldwide historically, today's revenue potential is considerably more constrained. Pfizer faces competition from Moderna and the Novavax-Sanofi protein vaccine for this smaller patient pool. The company's current share price sits 5.27% above its estimated value of $26.51, suggesting investors are paying a premium before actual uptake and commercial results become clear.

Associated Press
Aug 27th, 2026
FDA approves Pfizer-BioNTech XFG-adapted COVID-19 vaccine for high-risk groups

Pfizer and BioNTech have received US Food and Drug Administration (FDA) approval for their 2026-2027 COVID-19 vaccine targeting the XFG variant. The vaccine is approved for adults aged 65 and older, and individuals aged 5 to 64 with underlying conditions that increase risk of severe COVID-19 outcomes. The FDA approval is based on clinical, non-clinical and real-world data demonstrating the vaccine generates strong immune responses against currently circulating SARS-CoV-2 variants, including XFG and other contemporary lineages. The XFG variant was selected following FDA guidance for fall 2026 vaccine composition. The vaccine will begin shipping immediately and will be available in US pharmacies, hospitals and clinics within days. To date, more than five billion doses of COMIRNATY have been distributed globally.

Yahoo Finance
Aug 24th, 2026
Pfizer and J&J navigate patent cliffs with newer drugs offsetting blockbuster losses

Pfizer and Johnson & Johnson are navigating patent cliffs as key drugs lose exclusivity, with their latest results showing differing stages of transition. Pfizer's revenue excluding COVID products grew 5% operationally in Q2 2026, with newer medicines like Padcev and Vyndaqel contributing. The company expects $9.7 billion in cost savings through 2029 to support margins during the transition. Johnson & Johnson's Innovative Medicine sales rose 7.8%, despite Stelara revenue declining 55%. Tremfya sales surged 72.5% to $2 billion, helping offset losses alongside growth from oncology and neuroscience products. Johnson & Johnson raised 2026 guidance, with reported sales expected to reach $101.1 billion and adjusted EPS of $11.68. Its MedTech division provides additional diversification that pure pharmaceutical company Pfizer lacks, suggesting Johnson & Johnson's transition is more advanced.

Yahoo Finance
Aug 19th, 2026
Intel CEO invests $10M in shares as chipmaker posts 25% revenue growth driven by AI demand

Intel CEO Lip-Bu Tan purchased nearly $10 million worth of shares as part of the chipmaker's recent stock offering, signalling confidence in the company's turnaround. Intel recently reported revenues of $16.1 billion, growing 25% year-over-year, with its Data Centre and AI business unit seeing revenue surge nearly 60% to $6.3 billion. CoStar Group founder and CEO Andrew Florance purchased 83,300 shares totalling roughly $2.5 million. Pfizer CEO Albert Bourla similarly invested, purchasing 38,000 shares for just over $1 million. These insider purchases reflect executives' confidence in their companies' longer-term outlook, with investors often viewing such moves as a positive signal.